All In Biotech

Drug Trial Radar · NCT04481139

A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing Spondylitis

A Multicenter, Randomized, Double-blind, Placebo-controlled Adaptive Seamless Phase 2/3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Active Ankylosing Spondylitis Subjects

Last checked: Nov 19, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 504 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

504

Actual

Start

Oct 14, 2020

Primary completion

Nov 15, 2022

Study completion May 12, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with active ankylosing spondylitis.

Conditions

  • Ankylosing Spondylitis

Interventions

  • SHR0302Drug

    SHR0302, oral, once daily

  • SHR0302 placeboDrug

    SHR0302 placebo, oral, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Assessment in Ankylosing Spondylitis (ASAS) 20 response at Week 12.Time frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhanguo Li

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.